Suvretta reports 8.6% stake in Zura Bio
Suvretta Capital Management and related investors have filed an amended Schedule 13G reporting significant passive ownership in Zura Bio Limited.
Rhea-AI Filing Summary
Suvretta Capital Management and related investors have filed an amended Schedule 13G reporting significant passive ownership in Zura Bio Limited. Suvretta and its principal, Aaron Cowen, each report beneficial ownership of 5,567,001 Class A ordinary shares, representing 8.6% of the class, mainly through advisory clients.
Averill Master Fund, Ltd., an advisory client of Suvretta, reports beneficial ownership of 4,995,444 shares, or 7.7% of the class. Voting and dispositive power over these shares is shared, with no sole voting or dispositive authority reported for any of the three reporting persons.
The securities are held by Suvretta’s advisory clients, and the investors certify that the shares were not acquired and are not held for the purpose of changing or influencing control of Zura Bio, but instead on a passive basis.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Zura Bio (ZURA) does Suvretta Capital report?
What is Aaron Cowen’s reported beneficial ownership in Zura Bio (ZURA)?
Is Suvretta’s stake in Zura Bio (ZURA) intended to influence control of the company?
Why was an amended Schedule 13G filed for Zura Bio (ZURA)?
AI-generated analysis. How Rhea-AI works. Not financial advice.